CAIX-targeted PET/CT imaging in solid tumors
Official title: Carbonic Anhydrase IX-targeted PET/CT Imaging for Detecting Solid Tumors
Run by Zhongnan Hospital · NCT07833085 · Data updated 2026-11-12
Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Zhongnan Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | September 21, 2026 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2031 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT07833085 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with suspected or confirmed malignant solid tumors, good performance status (ECOG 0-1), and suitable organ function who can undergo PET imaging.
✕Probably not a fit
Patients with significant organ dysfunction, pregnancy, or conditions preventing PET imaging may not benefit from this imaging study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study evaluates a 68Ga-CAIX tracer for PET/CT imaging across patients with suspected or confirmed malignant solid tumors. The goal is to determine whether tumor uptake of the tracer correlates with tissue CAIX expression and tumor hypoxia. Participants must be adults with good performance status and no major organ dysfunction, and must be able to undergo PET imaging. The study is conducted at Zhongnan Hospital, Wuhan University, under a single sponsor with no listed collaborators.
Why it matters
Potential benefit: If successful, the imaging approach could improve tumor detection and characterization by highlighting CAIX-expressing hypoxic regions.
How similar studies have gone: CAIX-targeted imaging has shown promise in preliminary studies for identifying hypoxic tumor regions, but broader validation is ongoing.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology; * Age of 18 years and above, both male and female are eligible; * The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points; * Research participants voluntarily sign informed consent forms or have their parents/children/legal guardians sign informed consent forms, and are able to complete the trial according to the requirements of the research protocol. Exclusion Criteria: * Participants with severe liver and kidney dysfunction and cardiac dysfunction; * Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans; * Pregnant or lactating women; * Other situations that researchers believe should be excluded and documented.
Where it's running
-
Zhongnan hospital of Wuhan University
Wuhan, Hubei, China Recruiting
Study contacts
- Principal investigator: Yong He, MD, PhD — Zhongnan Hospital
- Study coordinator: Chongjiao Li, MD, PhD
- Email: LCJ0301@163.com
- Phone: +86-27-67812698
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
Brain-avoiding proton craniospinal irradiation for leptomeningeal metastases
This study tests BRAVO pCSI, a proton therapy approach that avoids certain brain regions, to see if it helps adults with leptomeningeal metastases from solid tumors.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
-
Testing MGC026 in patients with advanced solid tumors
This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.